Shares of Eurofins Scientific fell 6.0% to trade at €66.35 following the release of the company’s first-half 2026 results, as investors reacted to growth figures that came in below consensus.
Summary
The group recorded organic revenue growth of 2.7% for the first six months of the year, short of the analyst consensus of roughly 4.2%. Second-quarter organic growth of about 3% also missed forecasts. A notable area of concern was the biopharma testing segment, which moved to a sequential decline of -1.1% in Q2 after expanding 1.1% in Q1. Total first-half revenue of approximately €3.7 billion was broadly in line with consensus estimates. On the margin side, adjusted EBITDA rose 8% year-on-year, driving an improvement in the adjusted EBITDA margin to 23.7% from 22.4% a year earlier. Management reiterated full-year guidance calling for mid-single-digit organic growth and continued margin expansion toward the 2027 target of 24%.
Results and segment dynamics
Eurofins’ H1 organic growth rate of 2.7% contrasted with the consensus figure of about 4.2%, a shortfall that appears central to the market’s negative reaction. The Q2 organic expansion of around 3% likewise fell short of expectations. The biopharma testing division, which had shown modest growth of 1.1% in Q1, swung to a -1.1% decline in Q2 on a sequential basis, a reversal in one of the company’s historically higher-growth areas that heightened investor concern despite overall revenue holding near €3.7 billion for the half.
Profitability and guidance
Profitability metrics provided some offset to the top-line disappointment. Adjusted EBITDA increased by 8% year-on-year and the adjusted EBITDA margin improved to 23.7% from 22.4% in the prior year period. Management affirmed full-year guidance of mid-single-digit organic growth and signaled expectations for continued margin expansion toward the stated 2027 margin objective of 24%.
Market context and share movement
Weakness in Eurofins’ growth trajectory coincided with a risk-averse tone across global equities. U.S. indices were modestly lower on the day, with the S&P 500 off 0.3%, the Dow Jones down 0.4%, and the Nasdaq lower by 0.3%. The Paris-listed CAC 40 has also faced headwinds in recent sessions amid mixed European earnings reports and ongoing macro uncertainty. Taken together, the organic growth miss, softness in the biopharma segment, and a cautious market backdrop prompted a pronounced selloff in Eurofins shares, driving the stock toward the lower end of its intraday range of €66.20–€71.14 and leaving it well below its 52-week high of €74.32.
Key points
- Eurofins recorded H1 organic revenue growth of 2.7%, below the consensus expectation of about 4.2%.
- The biopharma testing segment shifted to a -1.1% sequential decline in Q2 after 1.1% growth in Q1, contributing to investor disappointment.
- Adjusted EBITDA rose 8% year-on-year and the margin improved to 23.7%, while management confirmed mid-single-digit organic growth guidance and continued margin expansion toward a 24% 2027 target.
Risks and uncertainties
- Top-line momentum is weaker than expected, particularly in biopharma testing, which could pressure revenue growth for the remainder of the year - relevant to healthcare and lab services sectors.
- A cautious macro and market environment, reflected in modest declines across major U.S. indices and headwinds in the CAC 40, may exacerbate share-price volatility for European-listed companies.
The facts in the release leave a mixed picture: improved margin performance and confirmed guidance on one hand, and a material organic growth shortfall and segment-level reversal on the other, which together led to meaningful downward pressure on the stock.